# Alpha Tau Medical Ltd. (DRTS)

> Source: Nexqual · https://nexqual.com/DRTS · data as of 2026-11-18 20:53 UTC · cite as "Nexqual, Alpha Tau Medical Ltd. (DRTS), nexqual.com/DRTS" · informational, not investment advice.

## What changed for DRTS since Aug 31, 2025
The built-in knowledge of several widely used AI models ends around Aug 31, 2025. Everything below is newer, dated and sourced (as of Nov 18, 2026).

- Alpha Tau Medical Ltd. (DRTS) stock went from USD 3.42 (close of the week of Aug 25, 2025, split-adjusted) to USD 12.13, a +254.7% price change; the S&P 500 (SPY) moved +14.8% over the same period.
- In the latest 13F period (Q3 2026), 1 of 80 superinvestors tracked by Nexqual hold DRTS; 0 opened new positions, 0 added and 1 reduced.
- Analyst actions on DRTS in the last 120 days: 5 (3 upgrades or target raises, 0 downgrades or target cuts); most recent Piper Sandler, Nov 11, 2026.

**Price:** USD 12.13 (+0.33% today) · US market open, as of November 18, 2026 at 20:53 UTC; quotes may be delayed. Prev close 12.09 · day 11.82–12.22 · 52w 3.43–15.79 · market cap $1.12B · NCM

## Key facts
- 1 of 80 tracked superinvestors hold DRTS (13F, Q3 2026): 0 new, 0 added, 1 reduced, 0 unchanged.
- Insider open-market sales, last ~7 months: 9 Form 4 filings, $1.6M; 1 not under a Rule 10b5-1 plan ($352K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Total return with dividends: 1Y +228.3% vs S&P 500 +11.9%; 5Y +21.9% vs S&P 500 +66.7%.
- Next earnings: 2026-11-19 (date not yet confirmed by the company), EPS estimate USD -0.15, revenue estimate $167K. All companies reporting that day: https://nexqual.com/earnings/2026-11-19
- Dividend: DRTS paid no cash dividend in the last five years.
- Short interest: 6.10% of float (as of 2026-10-30), 8.6 days to cover.

## Superinvestors (SEC 13F-HR, Q3 2026)
1 of 80 tracked investors hold DRTS. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Polen Capital | Polen Capital Management | 0.04% | $3.2M | Reduced -2.0% |

## Insider sales (SEC Form 4, open-market, last ~7 months)
8 of 9 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-08-21 | Levy Raphi | Chief Financial Officer | 2,871 | $43K | 3.1% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-08-11 | Levy Raphi | Chief Financial Officer | 17,730 | $248K | 16.4% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-07-06 | Levy Raphi | Chief Financial Officer | 2,270 | $32K | 2.5% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-07-02 | Levy Raphi | Chief Financial Officer | 17,873 | $232K | 16.5% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-07-01 | Levy Raphi | Chief Financial Officer | 2,127 | $28K | 2.3% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-06-30 | Levy Raphi | Chief Financial Officer | 20,000 | $240K | 18.2% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-06-25 | Levy Raphi | Chief Financial Officer | 20,000 | $220K | 15.4% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-06-23 | Levy Raphi | Chief Financial Officer | 17,500 | $167K | 11.8% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-06-03 | Levy Raphi | Chief Financial Officer | 32,500 | $352K | 18% | No | Too little history (no open-market trades in 2023–2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-11-11 | Piper Sandler | Upgrade | Neutral → Overweight | $8 → $22 |
| 2026-10-20 | HC Wainwright & Co. | Reiterated | Buy | $16 |
| 2026-09-03 | Barclays | Target raised | Overweight | $17 → $30 |
| 2026-08-11 | HC Wainwright & Co. | Target raised | Buy | $15 → $16 |
| 2026-07-22 | HC Wainwright & Co. | Reiterated | Buy | $15 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-11-18) | 5Y (from 2021-11-15) |
|---|---|---|
| Total return | +228.3% | +21.9% |
| S&P 500 (SPY) | +11.9% | +66.7% |
| Per year | +228.5% | +4.0% |
| Volatility (annualized) | 76.2% | 70.3% |
| Max drawdown | -23.9% (Feb 2026→Mar 2026) | -84.8% (Mar 2022→Aug 2024) |

## Dividends
DRTS paid no cash dividend in the last five years.

## Short interest
3,920,240 shares sold short, 6.10% of the float, as of Oct 30, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 30, 2026): 3,447,381 shares (+13.7%). Days to cover: 8.6 (short shares ÷ average daily volume).

## Peers (Biotechnology)
KOD (Kodiak Sciences Inc) USD 97.7 +0.93% · BLTE (Belite Bio, Inc) USD 156.45 -0.81% · ORKA (Oruka Therapeutics, Inc.) USD 95.68 -0.67% · IMVT (Immunovant, Inc.) USD 33.24 +0.08% · AXSM (Axsome Therapeutics, Inc.) USD 133.89 -1.52% · IBRX (ImmunityBio, Inc.) USD 6.7 +6.95%

## More
Full page: https://nexqual.com/DRTS · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in DRTS's own 20-F filed 2026-03-09 (https://www.sec.gov/Archives/edgar/data/1871321/000121390026025174/ea0279271-20f_alpha.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | HekaBio | "in our core markets, including the United States and Europe, except for our agreement with HekaBio KK with respect to the commercialization" |
| Partner | MIM Software | "and patent applications related to our Alpha DaRT technology and, other than our collaboration agreement with MIM Software Inc. ("MIM")" |
| Partner | Althera Medical | "In addition, under the intellectual property purchase agreement with Althera, we assumed all of Althera's liabilities towards the" |
| Partner | Oramed | "For example on April 24, 2025, we entered into the Oramed Purchase Agreement with Oramed for the sale by us of 14,110,121 Shares, in a" |

Other companies that name DRTS in their own reports (relationship from DRTS's side):

| Relationship | Company | Their filing | Sentence |
|---|---|---|---|
| partner | ORAMED PHARMACEUTICALS INC. (ORMP) | 10-K 2026-03-26 | "subsidiary, Oramed Ltd entered into a share purchase agreement with Alpha Tau Medical Ltd. (Nasdaq: DRTS), or Alpha Tau, a clinical-stage" |

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-0.15 | $-0.14 | −$0.01 | $166,670 | 4 |
| Next quarter (ends 2026-12-31) | $-0.16 | $-0.15 | −$0.01 | $333,330 | 4 |
| Current fiscal year (ends 2026-12-31) | $-0.96 | $-0.88 | −$0.09 | $500,000 | 5 |
| Next fiscal year (ends 2027-12-31) | $-0.54 | $-0.53 | −$0.01 | $10.7M | 5 |

## Options: expected move (Cboe, 15-min delayed)

Expected move by 2026-11-20 (includes earnings 2026-11-19): ±7.7%.

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-11-20 | 2 | 106.7% | ±7.7% |
| 2026-12-18 | 30 | 76.4% | ±18.2% |
| 2027-01-15 | 58 | 72.3% | ±23.6% |
| 2027-02-19 | 93 | 64.7% | ±26.5% |
| 2027-05-21 | 184 | 66.8% | ±38.0% |

## Earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | −$0.50 | −$0.14 | Miss −257.1% | — |
| — | Quarter ended Mar 31, 2026 | −$0.26 | −$0.12 | Miss −116.7% | — |
| — | Quarter ended Dec 31, 2025 | −$0.14 | −$0.12 | Miss −16.7% | — |
| — | Quarter ended Sep 30, 2025 | −$0.14 | −$0.12 | Miss −16.7% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

## Recent SEC filings (last 120 days)
| Filed | Form | What it says | Filing |
|---|---|---|---|
| 2026-11-16 | 6-K | Current report (foreign issuer) · period ended Nov 16, 2026 | https://www.sec.gov/Archives/edgar/data/1871321/000121390026120250/0001213900-26-120250-index.htm |
| 2026-11-16 | 6-K | Current report (foreign issuer) · period ended Nov 16, 2026 | https://www.sec.gov/Archives/edgar/data/1871321/000121390026120072/0001213900-26-120072-index.htm |
| 2026-11-12 | 6-K | Current report (foreign issuer) · period ended Nov 12, 2026 | https://www.sec.gov/Archives/edgar/data/1871321/000121390026118478/0001213900-26-118478-index.htm |
| 2026-10-29 | 6-K | Current report (foreign issuer) · period ended Oct 29, 2026 | https://www.sec.gov/Archives/edgar/data/1871321/000121390026113681/0001213900-26-113681-index.htm |
| 2026-10-22 | 6-K | Current report (foreign issuer) · period ended Oct 22, 2026 | https://www.sec.gov/Archives/edgar/data/1871321/000121390026111493/0001213900-26-111493-index.htm |
| 2026-10-19 | 6-K | Current report (foreign issuer) · period ended Oct 19, 2026 | https://www.sec.gov/Archives/edgar/data/1871321/000121390026110531/0001213900-26-110531-index.htm |
| 2026-08-31 | 6-K | Current report (foreign issuer) · period ended Aug 31, 2026 | https://www.sec.gov/Archives/edgar/data/1871321/000121390026095370/0001213900-26-095370-index.htm |
| 2026-08-10 | 6-K | Current report (foreign issuer) · period ended Jun 30, 2026 | https://www.sec.gov/Archives/edgar/data/1871321/000121390026087224/0001213900-26-087224-index.htm |
| 2026-08-10 | 6-K | Current report (foreign issuer) · period ended Aug 10, 2026 | https://www.sec.gov/Archives/edgar/data/1871321/000121390026086947/0001213900-26-086947-index.htm |
| 2026-07-21 | 6-K | Current report (foreign issuer) · period ended Jul 21, 2026 | https://www.sec.gov/Archives/edgar/data/1871321/000121390026079822/0001213900-26-079822-index.htm |
Source: SEC EDGAR. Quotes are the opening words of each item as filed.
